Aemetis (NASDAQ:AMTX) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Aemetis shares fell below their 200-day moving average, trading as low as $1.2550 and last changing hands at $1.27, down 7.3%. The stock’s 50-day and 200-day moving averages were $1.79 and $2.02, respectively.
• Analyst sentiment remains mixed, with one Buy and one Sell rating producing a consensus “Hold” rating; the consensus price target is $11.88. Weiss Ratings maintained a “sell” rating, while Wall Street Zen upgraded the stock to “hold.”
• Aemetis reported a quarterly loss of $0.13 per share, better than the expected $0.29 loss, but revenue of $62.7 million missed estimates of $67.69 million. Institutional investors own 27.02% of the company, with several firms recently increasing or initiating positions.

Shares of Aemetis, Inc (NASDAQ:AMTX - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.02 and traded as low as $1.2550. Aemetis shares last traded at $1.27, with a volume of 1,464,838 shares trading hands.

Wall Street Analysts Forecast Growth

AMTX has been the subject of several research reports. Weiss Ratings restated a "sell (e+)" rating on shares of Aemetis in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Aemetis from a "sell" rating to a "hold" rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aemetis has a consensus rating of "Hold" and a consensus price target of $11.88.

Aemetis Trading Down 7.3%

The stock has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $2.02. The stock has a market capitalization of $91.66 million, a price-to-earnings ratio of -1.40 and a beta of 1.82.

Aemetis (NASDAQ:AMTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The specialty chemicals company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.16. The business had revenue of $62.70 million during the quarter, compared to analyst estimates of $67.69 million. Sell-side analysts expect that Aemetis, Inc will post -0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMTX. Bank of New York Mellon Corp purchased a new stake in Aemetis in the 2nd quarter worth approximately $283,000. Bank of America Corp DE boosted its stake in shares of Aemetis by 148.3% during the 1st quarter. Bank of America Corp DE now owns 101,486 shares of the specialty chemicals company's stock valued at $324,000 after buying an additional 60,611 shares during the period. Royal Bank of Canada boosted its stake in shares of Aemetis by 10,632.5% during the 1st quarter. Royal Bank of Canada now owns 8,908 shares of the specialty chemicals company's stock valued at $28,000 after buying an additional 8,825 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Aemetis during the 1st quarter valued at $272,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Aemetis during the 1st quarter valued at $33,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc is a renewable fuels and renewable chemicals company focused on developing and operating low-carbon production facilities. Its activities include the production of renewable natural gas, renewable fuels, ethanol, and other products designed to reduce greenhouse gas emissions from transportation and industrial operations.

The company operates an ethanol production facility in California's Central Valley and develops dairy-based biogas and renewable natural gas projects that capture methane from agricultural waste.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.